Triastek is a global healthcare company, developing medicines with proprietary, pioneering 3D printing technology. We are dedicated to revolutionizing the development and manufacturing of pharmaceutical products and unlocking the next generation of medicines through the use of 3D printing technology. Our state-of-the-art technology, called Melt-Extrusion Deposition (MED®), allows us to develop medicines in a layered construction to enable the controlled and precise release of treatments. Our 3D printing technology platform encompasses dosage form design, digital pharmaceutical product development, and intelligent manufacturing. We are the only specialized 3D printing pharmaceutical company in China, and the only China-based pharmaceutical company selected in the US Food and Drug Administration (FDA) Emerging Technology Program. Triastek’s vision is to become the most influential intelligent pharmaceutical enterprise in the world. We have three potentially transformative 3D-printed drugs in the pipeline and all three drugs (T19, T20, and T21) have received IND clearance from the FDA. In addition, T19 has received IND approval from NMPA in China.